This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Franz Schnetzinger
Director Analytical Development at Gyroscope Therapeutics


Franz joined Gyroscope Therapeutics in January 2017 to lead the development of the control strategy of Gyroscope’s AAV gene therapy vector programmes and to coordinate in-house and external analytical method development. He joined from GSK where he led third party analytical development and validation work for two lentiviral based ex-vivo autologous gene therapy programmes whilst supporting the MAA writing process of Strimvelis. Prior to GSK Franz worked at Baxter AG, Austria, where he developed, validated, and executed release methods for vaccines and recombinant proteins.

Franz holds a BSc in Bioengineering & Bioinformatics from University of Applied Sciences Vienna, Austria, and a MSc in Analytical Biotechnology from Cranfield University, UK.

Agenda Sessions

  • Speaker Q&A - Gene Therapy Analytics

  • The Case for rAAV Titration by HPLC